etanidazole has been researched along with Fibrosarcoma in 16 studies
Etanidazole: A nitroimidazole that sensitizes hypoxic tumor cells that are normally resistant to radiation therapy.
etanidazole : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2-nitro-1H-imidazol-1-yl)acetic acid with the amino group of ethanolamine. Used as a radiosensitising agent for hypoxic tumour cells.
Fibrosarcoma: A sarcoma derived from deep fibrous tissue, characterized by bundles of immature proliferating fibroblasts with variable collagen formation, which tends to invade locally and metastasize by the bloodstream. (Stedman, 25th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| ") was administered just prior to an alkylating agent, the combination treatment produced significantly more tumor cell killing across the dosage range of each alkylating agent tested compared with the alkylating agent alone." | 5.28 | Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma. ( Bubley, G; Coleman, CN; Eder, JP; Frei, E; Herman, TS; Holden, SA; Tanaka, J; Teicher, BA, 1991) |
| "We have examined the ability of misonidazole (MISO) or etanidazole (ETA) to improve the antitumor efficacy of cisplatin (CDDP), hyperthermia, and radiation in the FSaIIC murine fibrosarcoma." | 3.68 | Addition of 2-nitroimidazole radiosensitizers to cis-diamminedichloroplatinum(II) with radiation and with or without hyperthermia in the murine FSaIIC fibrosarcoma. ( Herman, TS; Holden, SA; Jones, SM; Pfeffer, MR; Teicher, BA, 1990) |
| "The abilities of misonidazole, Ro 05-9963, Ro 03-8799 and Sr-2508 to enhance the action of the drugs cyclophosphamide (CY) and melphalan (L-PAM) have been compared in two mouse fibrosarcomas at acute and chronic sensitizer doses." | 3.67 | A comparison of the ability of some radiosensitizers undergoing clinical trials to act as chemosensitizers. ( Hinchliffe, M; McNally, NJ, 1984) |
| "In KHT tumors, perfused vessel numbers decreased significantly at 30 min post-hydralazine, then recovered somewhat by 60 min." | 1.31 | Influence of hydralazine administration on oxygenation in spontaneous and transplanted tumor models. ( Fenton, BM, 2001) |
| ") was administered just prior to an alkylating agent, the combination treatment produced significantly more tumor cell killing across the dosage range of each alkylating agent tested compared with the alkylating agent alone." | 1.28 | Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma. ( Bubley, G; Coleman, CN; Eder, JP; Frei, E; Herman, TS; Holden, SA; Tanaka, J; Teicher, BA, 1991) |
| "Etanidazole was more cytotoxic at pH 6." | 1.28 | Effect of pH, oxygenation, and temperature on the cytotoxicity and radiosensitization by etanidazole. ( Herman, TS; Holden, SA; Teicher, BA, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (12.50) | 18.7374 |
| 1990's | 7 (43.75) | 18.2507 |
| 2000's | 7 (43.75) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mahy, P | 2 |
| De Bast, M | 2 |
| Gallez, B | 1 |
| Gueulette, J | 1 |
| Koch, CJ | 2 |
| Scalliet, P | 1 |
| Grégoire, V | 2 |
| Barthel, H | 1 |
| Wilson, H | 1 |
| Collingridge, DR | 1 |
| Brown, G | 1 |
| Osman, S | 1 |
| Luthra, SK | 1 |
| Brady, F | 1 |
| Workman, P | 1 |
| Price, PM | 1 |
| Aboagye, EO | 1 |
| Gillart, J | 1 |
| Labar, D | 1 |
| Hinchliffe, M | 1 |
| McNally, NJ | 1 |
| Rasey, JS | 1 |
| Hofstrand, PD | 1 |
| Chin, LK | 1 |
| Tewson, TJ | 1 |
| Yapp, DT | 1 |
| Lloyd, DK | 1 |
| Zhu, J | 1 |
| Lehnert, S | 1 |
| Fenton, BM | 3 |
| Lord, EM | 2 |
| Paoni, SF | 2 |
| Nadal-Desbarats, L | 1 |
| Poptani, H | 1 |
| Oprysko, P | 1 |
| Jenkins, WT | 1 |
| Busch, TM | 1 |
| Nelson, DS | 1 |
| Glickson, JD | 1 |
| Evans, SM | 1 |
| Teicher, BA | 6 |
| Herman, TS | 6 |
| Tanaka, J | 1 |
| Eder, JP | 1 |
| Holden, SA | 4 |
| Bubley, G | 2 |
| Coleman, CN | 2 |
| Frei, E | 2 |
| Shulman, L | 1 |
| Pfeffer, MR | 2 |
| Jones, SM | 2 |
| Khandekar, V | 1 |
| Chapnick, RM | 1 |
| Kalick, GS | 1 |
| Rabow, A | 1 |
16 other studies available for etanidazole and Fibrosarcoma
| Article | Year |
|---|---|
In vivo colocalization of 2-nitroimidazole EF5 fluorescence intensity and electron paramagnetic resonance oximetry in mouse tumors.
Topics: Algorithms; Animals; Cell Hypoxia; Charcoal; Computer Graphics; Disease Models, Animal; Electron Spi | 2003 |
In vivo evaluation of [18F]fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomography.
Topics: Animals; Breast Neoplasms; Cell Hypoxia; Etanidazole; Fibrosarcoma; Fluorine Radioisotopes; Mice; Mi | 2004 |
Detection of tumour hypoxia: comparison between EF5 adducts and [18F]EF3 uptake on an individual mouse tumour basis.
Topics: Animals; Cell Hypoxia; Drug Evaluation, Preclinical; Etanidazole; Fibrosarcoma; Fluorescent Antibody | 2006 |
A comparison of the ability of some radiosensitizers undergoing clinical trials to act as chemosensitizers.
Topics: Animals; Antineoplastic Agents; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Synergism; | 1984 |
Characterization of [18F]fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia.
Topics: Animals; Binding Sites; Blood-Brain Barrier; Cell Hypoxia; Chromatography, High Pressure Liquid; Con | 1999 |
Radiosensitization of a mouse tumor model by sustained intra-tumoral release of etanidazole and tirapazamine using a biodegradable polymer implant device.
Topics: Animals; Antineoplastic Agents; Cell Hypoxia; Drug Implants; Etanidazole; Female; Fibrosarcoma; Mice | 1999 |
Enhancement of tumor perfusion and oxygenation by carbogen and nicotinamide during single- and multifraction irradiation.
Topics: Animals; Carbocyanines; Carbon Dioxide; Cell Hypoxia; Combined Modality Therapy; Dose Fractionation, | 2000 |
Influence of hydralazine administration on oxygenation in spontaneous and transplanted tumor models.
Topics: Animals; Carbocyanines; Cell Hypoxia; Etanidazole; Female; Fibrosarcoma; Fluorescent Dyes; Hydralazi | 2001 |
Effects of radiation on tumor intravascular oxygenation, vascular configuration, development of hypoxia, and clonogenic survival.
Topics: Animals; Biological Transport; Blood Vessels; Cell Hypoxia; Etanidazole; Female; Fibrosarcoma; Gamma | 2001 |
Effects of hyperglycemia on oxygenation, radiosensitivity and bioenergetic status of subcutaneous RIF-1 tumors.
Topics: Animals; Cell Division; Energy Metabolism; Etanidazole; Female; Fibrosarcoma; Flow Cytometry; Glucos | 2002 |
Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma.
Topics: Alkylating Agents; Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carbon Diox | 1991 |
Effect of pH, oxygenation, and temperature on the cytotoxicity and radiosensitization by etanidazole.
Topics: Animals; Benzimidazoles; Cell Division; Cell Line; Cell Survival; Etanidazole; Fibrosarcoma; Flow Cy | 1991 |
Combination of etanidazole with cyclophosphamide and platinum complexes.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Cells; Carboplatin | 1991 |
Addition of 2-nitroimidazole radiosensitizers to cis-diamminedichloroplatinum(II) with radiation and with or without hyperthermia in the murine FSaIIC fibrosarcoma.
Topics: Animals; Cell Survival; Cisplatin; Combined Modality Therapy; Drug Therapy, Combination; Etanidazole | 1990 |
Effect of acidic pH on radiosensitization of FSaIIC cells in vitro by misonidazole, etanidazole, or cis-diamminedichloroplatinum (II).
Topics: Animals; Cell Line; Cell Survival; Cisplatin; Etanidazole; Fibrosarcoma; Hydrogen-Ion Concentration; | 1990 |
Addition of misonidazole, etanidazole, or hyperthermia to treatment with fluosol-DA/carbogen/radiation.
Topics: Animals; Carbon Dioxide; Combined Modality Therapy; Drug Combinations; Etanidazole; Fibrosarcoma; Fl | 1989 |